Canadian estimates of health care utilization costs for rheumatoid arthritis patients with and without therapy with biologic agents

Arthritis Care and Research

Volumn 66, Issue 9, 2014, Pages 1319-1327

  Ohinmaa, Arto E ^a   Thanh, Nguyen X ^a   Barnabe, Cheryl ^b   Martin, Liam ^b   Russell, Anthony S ^a   Barr, Susan G ^b   Maksymowych, Walter P ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BACKACHE; BIOLOGICAL THERAPY; CANADIAN; CONTROLLED STUDY; DEPRESSION; DISABILITY; EMERGENCY WARD; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HOSPITALIZATION COST; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; OUTPATIENT CARE; PHYSICAL CAPACITY; PHYSICIAN; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CANADA; COST OF ILLNESS; DATABASES, FACTUAL; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED;

EID: 84904816660     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22293     Document Type: Article

References (26)

1. Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K,. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 1169-75.
2. Hallert E, Husberg M, Skogh T,. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project). Rheumatology (Oxford) 2006; 45: 325-31.
3. Hulsemann JL, Ruof J, Zeidler H, Mittendorf T,. Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'. Rheumatol Int 2006; 26: 704-11.
4. Verstappen SM, Verkleij H, Bijlsma JW,. Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann Rheum Dis 2004; 63: 817-24.
5. Pugner KM, Scott DI, Holmes JW, Hieke K,. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000; 29: 305-20.
6. Kobelt G, Richard B, Peeters P, Sany J,. Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. Joint Bone Spine 2008; 75: 408-15.
7. Beresniak A, Gossec L, Goupille P, Saraux A, Bamberger M, Bregman B, et al. Direct cost-modeling of rheumatoid arthritis according to disease activity categories in France. J Rheumatol 2011; 38: 439-45.
8. Barnabe C, Thanh NX, Ohinmaa A, Homik J, Barr S, Martin L, et al. Healthcare system costs in Canada are reduced when rheumatoid arthritis patients achieve sustained remission. Ann Rheum Dis 2013; 72: 1664-8.
9. Barr SG, Martin L, Chung C, Maksymowych WP,. Mandatory pharmacosurveillance: a Canadian model for access to therapy and research. Clin Exp Rheumatol 2004; 22 Suppl: 44-8.
10. Wolfe F,. Data collection and utilization: a methodology for clinical practice and clinical research. In:, Wolfe F, Pincus T, Dekker M, editors. Rheumatoid arthritis: pathogenesis, assessment, outcome and treatment. New York: Marcel Dekker; 1994. p. 463-514.
11. Hays R, Sherbourne C, Mazel R,. The RAND 36-item health survey 1.0. Health Econ 1993; 2: 217-27.
12. Brooks R,. EuroQol: the current state of play. Health Policy 2006; 37: 53-72.
13. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN,. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003; 49: 156-63.
14. Alberta Health and Wellness. Alberta case cost report for 2006/2007 hospital activity. Government of Alberta. 2009. URL: http://www.ahw.gov.ab.ca/ IHDA-Retrieval/selectCategory.do.
15. Alberta Health Care Insurance Plan. Schedule of medical benefits as of 2011/06/01. URL: http://www.health.alberta.ca/professionals/SOMB.html.
16. Statistics Canada. Consumer Price Index, by province. 2011. URL: http://www40.statcan.gc.ca/l01/cst01/econ09a-eng.htm.
17. Austin PC,. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399-424.
18. Becker SO, Ichino A,. Estimation of average treatment effects based on propensity scores. Stata J 2002; 2: 358-77.
19. Caliendo M, Kopeinig S,. Some practical guidance for the implementation of propensity score matching. 2005. URL: http://ftp.iza.org/dp1588.pdf.
20. Canadian Institute for Health Information. National health expenditure trends, 1975 to 2012. Ottawa: CIHI; 2012.
21. Rat AC, Boissier MC,. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine 2004; 71: 518-24.
22. Lundkvist J, Kastang F, Kobelt G,. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 2008; 8 Suppl: S49-60.
23. Yelin E, Wanke LA,. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42: 1209-18.
24. Kavanaugh A,. Health economics: implications for novel antirheumatic therapies. Ann Rheum Dis 2005; 64: iv65-9.
25. Clarke AE, Zowall H, Levinton C, Assimakopoulos H, Sibley JT, Haga M, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997; 24: 1051-60.
26. Clarke AE, Levinton C, Joseph L, Penrod J, Zowall H, Sibley JT, et al. Predicting the short term direct medical costs incurred by patients with rheumatoid arthritis. J Rheumatol 1999; 26: 1068-75.